SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000899243-20-017706
Filing Date
2020-06-25
Accepted
2020-06-25 20:01:10
Documents
1
Period of Report
2020-06-25

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 7350
  Complete submission text file 0000899243-20-017706.txt   9453
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Reporting) CIK: 0001055951 (see all company filings)

State of Incorp.: DE
Type: 3 | Act: 34 | File No.: 001-39344 | Film No.: 20990637

Mailing Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE, 54TH FLOOR NEW YORK NY 10022 212-739-6491
OrbiMed Capital GP VII LLC (Reporting) CIK: 0001760648 (see all company filings)

State of Incorp.: DE | Fiscal Year End: 1231
Type: 3 | Act: 34 | File No.: 001-39344 | Film No.: 20990638

Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Issuer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)